Management of atrial fibrillation

Heart

Volumn 92, Issue 8, 2006, Pages 1177-1182

  Lip, Gregory Y H ^a   Tello Montoliu, Antonio ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM ANTAGONIST; CARVEDILOL; CLOPIDOGREL; DIGOXIN; DILTIAZEM; ESMOLOL; FLECAINIDE; METOPROLOL; NEBIVOLOL; NONSTEROID ANTIINFLAMMATORY AGENT; PROPAFENONE; SOTALOL; VERAPAMIL; WARFARIN;

CLINICAL TRIAL; DOSE RESPONSE; EVIDENCE BASED MEDICINE; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART RATE; HEART RHYTHM; HUMAN; LUNG FIBROSIS; MEDICAL LITERATURE; MEDICAL SOCIETY; META ANALYSIS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; REVIEW; SCREENING TEST; STROKE; SYSTEMATIC REVIEW; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CARDIAC PACING, ARTIFICIAL; CATHETER ABLATION; FIBRINOLYTIC AGENTS; FORECASTING; HUMANS;

EID: 33746390901     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2005.071555     Document Type: Review

References (28)

1. Fuster V, Ryden LE, Asinger RW, et al. American College of Cardiology/American Heart Association/European Society of Cardiology Board. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary a report of the American College of Cardiology/American heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for practice guidelines and policy conferences (committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology, Circulation 2001;104:2118-50.
2. Freestone B, Lip GYH. Epidemiology and costs of cardiac arrhythmias. In: Lip GYH, Godtfredsen J, eds. Cardiac arrhythmias: a clinical approach. Edinburgh: Mosby, 2003:3-24.
3. Hobbs FD, Fitzmaurice DA, Mant J, et al. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess 2005;9:1-90. A Health Technology Assessment monograph on the largest trial of screening for AF in the elderly.
4. Morgan S, Mant D. Randomised trial of two approaches to screening for atrial fibrillation in UK general practice. Br J Gen Pract 2002;52:373-4, 377-80.
5. Swedberg K, Cleland J, Dargie H, et al for the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur Heart J 2005;26:1115-40.
6. Farshi R, Kistner D, Sarma JS, et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol 1999;33:304-10.
7. Corley SD, Epstein AE, DiMarco JP, et al for the AFFIRM Investigators. Relationships between sinus rhythm, treatment, and survival in the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study. Circulation 2004;109:1509-13.
8. Martinez-Marcos FJ, Garcia-Garmendia JL, Ortega-Carpio A, et al. Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol 2000;86:950-3.
9. Singh SN, Singh BN, Reda DJ, et al. Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (sotalol-amiodarone fibrillation efficacy trial (Safe-T)). Am J Cardiol 2003;92:468-72.
10. Alboni P, Botto GL, Baldi N, et al. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med 2004;351:2384-91.
11. Lim HS, Hamaad A, Lip GYH. Clinical review: clinical management of atrial fibrillation-rate control versus rhythm control. Crit Care 2004;8:271-9.
12. Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation. JAMA 2005;293:2634-40.
13. Karch MR, Zrenner B, Deisenhofer I, et al. Freedom from atrial tachyarrhythmias after catheter ablation of atrial fibrillation: a randomized comparison between 2 current ablation strategies. Circulation 2005;111:2875-80.
14. Hindricks G, Piorkowski C, Tanner H, et al. Perception of atrial fibrillation before and after radiofrequency catheter ablation: relevance of asymptomatic arrhythmia recurrence. Circulation 2005;12:307-13.
15. Wood MA, Brown-Mahoney C, Kay GN, et al. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis. Circulation 2000;101:1138-44.
16. Lip GYH, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Tnromb Res 2005;Sept 28 [Epub ahead of print] doi:10.1016/j.thromres.2005.08.007. The most recent meta-analysis of stroke prevention trials in AF.
17. Hart RG, Pearce LA, Rothbart RM, et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke prevention in atrial fibrillation investigators. J Am Coll Cardiol 2000;35:183-7.
18. Flaker GC, Belew K, Beckman K, et al for the AFFIRM Investigators. Asymptomatic atrial fibrillation: demographic features and prognostic information from the atrial fibrillation rollow-up investigation or rhythm management (AFFIRM) study. Am Heart J 2005;149:657-63.
19. Lip GY, Boos C. Antithrombotic treatment in atrial fibrillation. Heart 2006;92:155-61. Recent review of the data on thromboprophylaxis in AF.
20. Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 2004;110:2287-92.
21. Boos CJ, Lip GY. Targeting the renin-angiotensin-aldosterone system in atrial fibrillation: from pathophysiology to clinical trials. J Hum Hypertens 2005;19:855-9.
22. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005;45:1832-9.
23. Arima H, Hart RG, Colman S, et al. Perindopril-based blood pressure-lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke 2005;36:2164-9.
24. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol. The losartan intervention for end point reduction in hypertension (LIFE) study. J Am Coll Cardiol 2005;45:712-9.
25. Boos C, Anderson R, Lip GYH. Is atrial fibrillation an inflammatory disorder? Eur Heart J 2006;27:136-49. Recent comprehensive review of the data on the links between AF and inflammation.
26. Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003;108:3006-10.
27. Calo L, Bianconi L, Colivicchi F, et al. N-3 Fatty acids for the prevention of l atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol 2005;45:1723-8.
28. Ostermayer SH, Reisman M, Kramer PH, et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials. J Am Coll Cardiol 2005;46:9-14.